STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data
| Autor: | Ji Zhou, Zhenxin Wang, Sven Skog, Yu Wang, Zhongcheng Li, Guoqing Zhang, Wu Lh, Shunchang Jiao, Hongbo Ma, Ailian Hei, Shengjie Sun, Yi Hu, Ellen He, Jin Li |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty non-small-cell lung cancer (NSCLC) non-small cell lung cancer (NSCLC) survival radical resection (RR) 03 medical and health sciences 0302 clinical medicine Internal medicine Overall survival Carcinoma Medicine Prognostic biomarker Lung cancer Thymidine kinase 1 serum thymidine kinase 1 protein (STK1p) Lung business.industry medicine.disease respiratory tract diseases lung cancer 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Non small cell business thymidine kinase 1 (TK1) Research Article Biotechnology |
| Zdroj: | Future Science OA |
| ISSN: | 2056-5623 |
| DOI: | 10.2144/fsoa-2020-0130 |
| Popis: | Aim: A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs). Patients & methods: The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017. Results: Kaplan–Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS. Conclusion: STK1p is helpful in predicting OS of early/middle stages (I–IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs. Lay abstract Lung cancer is one of the most common types of tumors, with a high mortality rate. We investigate if thymidine kinase 1 in serum (STK1p) is a reliable prognostic marker for survival in non-small-cell lung carcinoma. We recruited 127 patients in this study. STK1p level was determined using a high-sensitive chemiluminescent dot blot assay. Patients with elevated STK1p values had worse overall survival, especially patients in the early/middle cancer stages. Analysis showed that STK1p is an independent prognostic factors for overall survival. We concluded that STK1p is helpful predicting the efficacy of treatment in non-small-cell lung carcinoma for those in the early/middle stages. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|